Life After Big Pharma: Why Going Small Was A Good Choice
Source: Life Science Leader
By Bill Breitenbach
After 25 years of working my way through major corporations in biopharma, I’ve made the jump from a massive organization to a small — or perhaps better said, a tiny — organization for an opportunity to launch a product that takes care of a very small population of children with congenital heart disease.
My previous organization had 40,000+ employees. At Mezzion Pharmaceuticals, I was employee No. 5 in the U.S., and we’re on our way to doubling that number.
access the Magazine Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.
Subscribe to Life Science Leader
X
Subscribe to Life Science Leader
This website uses cookies to ensure you get the best experience on our website. Learn more